Replies to post #383274 on Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

"How will the headline read?"

Here's my (highly educated) guess:

I emphasize that this is NOT a real PR (yet), just my speculation:

"Innovation Pharmaceuticals announces results of Phase II study of brilacidin in COVID-19

Analysis of the top lines results of this 120 patient study of brilacidin plus Standard of Care versus placebo and Standard of Care has now been completed.

Encouragingly, brilacidin proved effective in a number of patients hospitalized with COVID-19. However these results failed to reach significance.

This failure to reach significance was due to a more robust and pronounced effect in the placebo group than was anticipated, and therefore the study was not sufficiently powered to produce a statistically significant result. Additionally the requirement to use a lower dose of brilacidin than that used in previous Phase II studies resulted in lower serum levels than perhaps were necessary.

However retrospective analyses of some patient sub-sets have revealed some promising and encouraging directions for future research. For example, one-legged patients from Minsk not requiring ventilator support did better on brilacidin than on placebo.

Investigation of these promising avenues will require a Phase IIB clinical trial program and we are in the process of discussions with various entities regarding funding for this program."